India`s drug controller has granted emergency use authorisation for the Omicron-specific mRNA-based booster vaccine developed by Gennova Biopharmaceuticals under Mission Covid Suraksha, the Department of Biotechnology said on Tuesday.

The Department of Biotechnology (DBT) had facilitated establishing Gennova`s mRNA-based next-generation vaccine manufacturing for developing the platform technology from proof of concept till Phase I clinical trial of the prototype vaccine developed against the Wuhan strain, an official statement said.